Table 1.

Means and frequencies of participants' characteristics by androgen receptor status (N = 1467), Nurses' Health Study (1976–1997)

CharacteristicAR−AR+
n (%)313 (21.3)1154 (78.7)
Age at diagnosis, mean (n), y59.0 (313)60.8 (1154)
BMI at diagnosis, mean (na), kg/m226.6 (280)26.0 (1041)
Smoking, na (%)
Never138 (44.2)442 (38.5)
Past125 (40.1)482 (42.1)
Current49 (15.7)222 (19.4)
ER status, n (%)
Positive140 (44.7)1024 (88.7)
Negative173 (55.3)130 (11.3)
PR status, na (%)
Positive114 (36.7)830 (72.2)
Negative197 (63.3)319 (27.8)
HER2 status, na (%)
Positive46 (15.0)81 (7.1)
Negative260 (85.0)1059 (92.9)
Nodal involvement, n (%)
None212 (67.7)883 (76.5)
1–378 (24.9)220 (19.1)
4–916 (5.1)28 (2.4)
≥107 (2.3)23 (2.0)
Tumor size (cm), n (%)
≤2188 (60.1)814 (70.5)
>2125 (39.9)340 (29.5)
Histological grade, n (%)
I (low)22 (7.0)302 (26.2)
II (intermediate)127 (40.6)692 (60.0)
III (high)164 (52.4)160 (13.8)
Stageb, n (%)
I154 (49.2)682 (59.1)
II126 (40.3)394 (34.1)
III33 (10.5)78 (6.8)
Chemotherapy, na (%)
Yes141 (55.7)258 (27.4)
No112 (44.3)682 (72.6)
Hormone treatment, na (%)
Yes145 (58.2)672 (71.3)
No104 (41.8)270 (28.7)
Radiation treatment, na (%)
Yes114 (45.4)393 (41.6)
No137 (54.6)551 (58.4)

an does not add to total because of missing information.

bStage I: tumor size ≤ 2 cm and no nodal involvement;

stage II: tumor size ≤ 2 cm and 1–3 nodes or 2–4 cm and 0–3 nodes or 4+ cm and 0 nodes;

stage III: tumor size ≤ 2 cm and 4+ nodes or 2–4 cm and 4+ nodes or >4 cm and 1+ nodes.